Safety Study of Enoblituzumab (MGA271) in Combination With Ipilimumab in Refractory Cancer

Clinical trial NCT02381314 · COMPLETED

Trial details

NCT number: NCT02381314
Sponsor: MacroGenics
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Melanoma Non Small Cell Lung Cancer

Start date: 2015-03-26
Primary completion: 2017-11-09
Enrollment: 24

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.